Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2021 | Future perspectives on the use of human stem cells to model Alzheimer’s disease

Bryan Ng • 24 Mar 2021
ARUK 2021
Alzheimer’s Disease Dementia

Bryan Ng, PhD Student, University of Oxford, Oxford, UK, discusses the future steps of his work using human stem cells to model Alzheimer’s disease (AD). The use of tau-deficient cells to characterize cell phenotypes after treatment with amyloid beta oligomers can be expanded to analyze the mechanisms behind the observed phenotypes. For instance, a more in-depth evaluation of neuronal outgrowth impairment can be performed, and AD patient-derived stem cells can be considered for further analysis. This interview took place during the Alzheimer’s Research UK (ARUK) Conference 2021.

More from Bryan Ng

The challenges of Alzheimer’s disease animal models and the use of human stem cells
2:04
The challenges of Alzheimer’s disease animal models and the use of human stem cells
Bryan Ng • 24 Mar 2021
The impact of using human stem cells in dementia research
3:17
The impact of using human stem cells in dementia research
Bryan Ng • 24 Mar 2021
The effect of tau protein knockout on stem cells of healthy individuals
4:50
The effect of tau protein knockout on stem cells of healthy individuals
Bryan Ng • 24 Mar 2021
The benefit of using different models to study Alzheimer’s disease
2:29
The benefit of using different models to study Alzheimer’s disease
Bryan Ng • 24 Mar 2021

Related Videos

A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
10:28
A multimodal model to detect and stage Alzheimer's disease using MRI, acoustic signals, and genetics
Muhammad Umar Khan • 28 Aug 2026
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
3:25
Neuroprotective effects of aortic valve replacement: a propensity score-matched cohort study
Vikash Jaiswal • 26 Aug 2026
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
2:44
Neflamapimod receives ILAP designation in the UK for dementia with Lewy bodies
Jacqui Cannon • 5 Aug 2026
The Lewy Body Society's mission and impact
2:38
The Lewy Body Society's mission and impact
Jacqui Cannon • 5 Aug 2026

Choose your cookie settings

VJDementia uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJDementia is intended for healthcare professionals